Ablynx has announced additional results from the Phase III Hercules study with caplacizumab
Ablynx NV [Euronext Brussels and Nasdaq: ABLX] today announced additional results from the Phase III HERCULES study with caplacizumab, the…
Ablynx NV [Euronext Brussels and Nasdaq: ABLX] today announced additional results from the Phase III HERCULES study with caplacizumab, the…
Ablynx NV [Euronext Brussels and Nasdaq: ABLX] has announced that results from its Phase III HERCULES study of caplacizumab have been selected…